Literature DB >> 27127227

Response Assessment Criteria and Their Applications in Lymphoma: Part 1.

Mateen C Moghbel1, Lale Kostakoglu2, Katherine Zukotynski3, Delphine L Chen4, Helen Nadel5, Ryan Niederkohr6, Erik Mittra7.   

Abstract

The effectiveness of cancer therapy, both in individual patients and across populations, requires a systematic and reproducible method for evaluating response to treatment. Early efforts to meet this need resulted in the creation of numerous guidelines for quantifying posttherapy changes in disease extent, both anatomically and metabolically. Over the past few years, criteria for disease response classification have been developed for specific cancer histologies. To date, the spectrum of disease broadly referred to as lymphoma is perhaps the most common for which disease response classification is used. This review article provides an overview of the existing response assessment criteria for lymphoma and highlights their respective methodologies and validities. Concerns over the technical complexity and arbitrary thresholds of many of these criteria, which have impeded the long-standing endeavor of standardizing response assessment, are also discussed.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  CT; PERCIST; PET; RECIST; lymphoma

Mesh:

Year:  2016        PMID: 27127227     DOI: 10.2967/jnumed.115.166280

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma.

Authors:  Jun Tang; Darin Salloum; Brandon Carney; Christian Brand; Susanne Kossatz; Ahmad Sadique; Jason S Lewis; Wolfgang A Weber; Hans-Guido Wendel; Thomas Reiner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-21       Impact factor: 11.205

2.  Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294.

Authors:  Kiaran P McGee; Ken-Pin Hwang; Daniel C Sullivan; John Kurhanewicz; Yanle Hu; Jihong Wang; Wen Li; Josef Debbins; Eric Paulson; Jeffrey R Olsen; Chia-Ho Hua; Lizette Warner; Daniel Ma; Eduardo Moros; Neelam Tyagi; Caroline Chung
Journal:  Med Phys       Date:  2021-05-20       Impact factor: 4.071

3.  Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy.

Authors:  Murali Kesavan; Jan Boucek; William MacDonald; Andrew McQuillan; J Harvey Turner
Journal:  Diagnostics (Basel)       Date:  2017-05-12

Review 4.  Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology.

Authors:  John Kurhanewicz; Daniel B Vigneron; Jan Henrik Ardenkjaer-Larsen; James A Bankson; Kevin Brindle; Charles H Cunningham; Ferdia A Gallagher; Kayvan R Keshari; Andreas Kjaer; Christoffer Laustsen; David A Mankoff; Matthew E Merritt; Sarah J Nelson; John M Pauly; Philips Lee; Sabrina Ronen; Damian J Tyler; Sunder S Rajan; Daniel M Spielman; Lawrence Wald; Xiaoliang Zhang; Craig R Malloy; Rahim Rizi
Journal:  Neoplasia       Date:  2018-11-23       Impact factor: 5.715

5.  Inter-observer variability influences the Lugano classification when restaging lymphoma.

Authors:  Jacobus Möller; Tiaan Steyn; Nantes Combrinck; Gina Joubert; Alicia Sherriff; Jacques Janse van Rensburg
Journal:  SA J Radiol       Date:  2018-07-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.